Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20252024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) Feb 05, 2013 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 04, 2013 AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation Nov 12, 2012 Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol Nov 12, 2012 Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer Nov 07, 2012 Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets Nov 06, 2012 Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience Oct 15, 2012 NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study Sep 18, 2012 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City Sep 13, 2012 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012 Aug 09, 2012 Pagination First page « first Previous page ‹ previous … Page 30 Page 31 Page 32 Page 33 Current page 34 Page 35 Page 36 Page 37 Page 38 … Next page next › Last page last »